Kornimate/medical-research-clean huggingface dataset:
study of the application of magnetic fields for the treatment of parkinson's disease

Conditions: Parkinson's Disease; Quality of Life

Summary: the purpose of this study is to see if a device called the resonator can help to improve aspects of health and quality of life that are relevant to patients with parkinson's disease.

this clinical trial will evaluate a new non-invasive, non-significant risk, device therapy as an adjuvant symptomatic treatment for some of the signs and or symptoms of parkinson's disease (pd). the device utilizes patented technology involving extremely low level electromagnetic fields.

Eligibility criteria:
inclusion criteria: * idiopathic parkinson's disease * stable optimized anti-pd drugs for at least 4 weeks * pdq-39 summary index between 15 and 45 * ambulatory * willing to maintain regular medication regime throughout study * able to abstain from starting in new treatments to improve pd symptoms during course of study. * no prior surgical interventions for parkinson's disease * non-demented * minimum of 30 years of age, but not older than 85 * capable of giving full written consent exclusion criteria: * atypical parkinsonism such as progressive supranuclear palsy, multiple system atrophy, cbdg etc. * subjects may not have any of the following: active brain tumor, strokes, hydrocephalus, any other neurologic or non-neuro problem which may affect symptomatic expression of patients parkinsonism. * consumption of medications that can produce drug induced parkinsonism * chronic pain not associated with pd * current or past history of major psychiatric disturbance * no typical or non-typical anti-psychotics for treatment of drug induced psychosis. * chronic fatigue * epilepsy or history of epilepsy * seizures or taking medication for epilepsy * hiv or other autoimmune disorders * history of ect * uncontrolled hypertension * advanced pulmonary disease * unstable cardiac disease * prior surgical interventions for parkinson's disease * prosthetics or implants comprised of ferrous metals * pacemaker, vagus nerve stimulators, or other functional electrical stimulators such as those commonly used for pain * pregnant, breast feeding or planning pregnancy prior to study end * dementia, developmental disability, psychiatric disorder or other cognitive impairment * any significant medical condition that may require alteration of medical therapy during the study, or major medical condition which may interfere with the study activity.

Keywords: quality of life issues in parkinson's disease
the incidence of diabetes unawareness in patients hospitalized outside internal medicine services and related factors

Conditions: Diabetes; Hba1c; Inpatient Facililty Diagnoses

Summary: our purpose is to determine the prevalence of undiagnosed diabetes by checking hba1c in patients hospitalized outside internal medicine services and assess whether or not there is a difference between those without diabetes awareness and those with known diabetes in terms of age, sex, education status, presence of comorbidity and body mass index (bmi).

the study included 630 patients hospitalized outside internal medicine services and internal medicine side-branch services at or over the age of 18 whose anthropometric measurements could be made. the sociodemographic properties and comorbidities of the patients were recorded. their anthropometric measurements, fasting blood glucose and hba1c measurements were made. those with a previous diagnosis of diabetes were grouped as 'known diabetes', those without a known diabetes diagnosis but with an hba1c value of ≥6.5% during hospitalization were grouped as 'diabetes unaware', and those with an hba1c value of \<6.5% were grouped as 'no diabetes'. whether or not there were differences among the 3 groups based on sociodemographic characteristics, anthropometric measurements and disease statuses was examined.

Eligibility criteria:
inclusion criteria: * inpatients of units other than internal medicine services and internal medicine side-branch services at or * over the age of 18 * anthropometric measurements could be made were included exclusion criteria: * had comorbidities that could affect their anthropometric measurements (heart failure, edema, liver cirrhosis, cancer, cachexia, cushing syndrome, etc.), * who had been using steroids for more than a month, * pregnant * postoperative period

Keywords: diabetes mellitus diabetes unawareness i̇npatient hba1c
optimal patient turning for reducing hospital acquired pressure ulcers

Conditions: Pressure Ulcer

Summary: the purpose of this study is to test whether optimal patient turning, strictly every 2 hours with at least 15 minutes of tissue decompression, reduces the occurrence of hospital acquired pressure ulcers.

this single site, open label, two arm randomized control trial aims to evaluate whether optimal patient turning, strictly every 2 hours with at least 15 minutes of tissue decompression, reduces the occurrence of hospital acquired pressure ulcers. optimal turning procedures will be obtained with the use of a patient monitoring system (leaf healthcare, inc.) and compared to standard preventative care practices. sensors were placed on all participants as they were admitted to icu. a nurse's user dashboard was turned on for participants in the optimal turning group, but was not turned on for participants in the standard care group.

Eligibility criteria:
inclusion criteria: * adults (\>18 years of age) * admission to intensive care unit exclusion criteria: * children (\<18 years of age) * adhesive allergy * physical limitation for sensor application

Keywords: bed sores bedsores decubitus ulcer pressure sore
risk stratification of non st elevation acs with computed tomographic angiography (react)

Conditions: Acute Coronary Syndrome; Non-ST-Elevation Myocardial Infarction; Unstable Angina

Summary: the purpose of this project is to examine the effectiveness of computed tomographic angiography (cta) in patients with non-st elevation acute coronary syndrome (nste-acs). people who are hospitalized with this situation often require an angiogram to assess the heart and its arteries. recent advancements in technology have enabled cta to clearly define coronary artery anatomy with great accuracy and to guide treatment strategies in select patient populations. we are investigating that cta may be used, as an alternative to conventional angiograms, for the risk stratification of patients with high risk nste-acs. patients eligible for the study will be high risk nste-acs and awaiting an angiogram. enrolled patients will undergo cta prior to the angiogram. with each cta the patient will be injected with a small dose of an x-ray dye and will be asked to lie still on the "scanning bed" for a period of 5-10 minutes.


Eligibility criteria:
inclusion criteria: * high risk acs 1. angina \[accelerating pattern or prolonged episode (\> 20 minutes) or recurrent episode at rest or with minimal effort within preceding 24 hours\]; and (13) 2. elevated troponin - t (≥0.1 ug/l) or ecg changes consistent with ischemia \[st depression ≥ 0.1 mv, transient st segment elevation ≥ 0.1 mv (\< 20 minutes)\]) (11;13) * planned conventional invasive coronary angiography exclusion criteria: * age \< 18 years or lack of consent * renal insufficiency (gfr \< 60 ml/min) * allergy to contrast agent * refractory angina requiring urgent/emergent coronary angiography (as per treating physician) * contraindication to radiation exposure (e.g. pregnancy) * uncontrolled hr * previous cabg or pci/stent * atrial fibrillation, frequent atrial or ventricular ectopy (\> 1 / minute) * unable to perform 20 second breath-hold

Keywords: acs unstable angina nstemi
early haemadsorption in major burns

Conditions: Burns; Multiple Organ Failure; Shock; Organ Dysfunction Syndrome, Multiple; Renal Dysfunction; Cytokine Storm

Summary: major deep burns (\>20% body surface, involving deep skin layers) and associated severe inflammatory reaction and their complication are one of the biggest challenge of intensive care. haemoadsorption therapy, including the cytosorb treatment is a promising novel therapeutic approach, but only case-studies are available in the literature yet. based on data from septic shock patient treatment the investigators hypothesize that cytosorb is beneficial in early treatment of burns. the investigators aim to conduct a randomised-controlled study to assess the clinical effectiveness (based on score systems including mods, sofa, apache ii, kdigo, absi), 7 and 28 days survival, intensive care length of stay, length of mechanical ventilation, resuscitation fluid need and ino/vasopressor drug doses and the presence and severity of organ dysfunctions, particularly renal dysfunction. the investigatora plan to conduct basic research to elucidate the pathophysiological background of clinical effect, including the measurement of inflammatory and anti-inflammatory cytokines, presence and severity of oxidative stress (lipid peroxidation, protein oxidation, reduced/oxidised glutathion levels) and organ dysfunction markers (kidney injury molecule -1, neutrophil gelatinase-associated lipocalin, cystatin-c, uromodulin).


Eligibility criteria:
inclusion criteria: * informed consent of our patient or next of kin, * tbsa \>20% with 2/b depth of burn exclusion criteria: * non-thermal burn injury, * need for acute haemodialysis (intoxication), * immunosuppressive treatment, chronic steroid use (\> 3 months), * known malignant disease, * end-stage renal insufficiency or renal transplantation, * child c hepatic cirrhosis, * gravidity, * potentially lethal burn (baux index \>120) or comorbidities
indoor air quality and infectious aerosols in health care facilities

Conditions: Indoor Air Quality; Infectious Aerosols

Summary: outbreaks of emerging and re-remerging infectious diseases are frequently reported internationally in recent years, mainly due to global climate change, close human-livestock contact in developing countries, and globalization. thus prevention, monitoring and control of infectious diseases are in urgent need to protect public health. high exposure risk to various infectious agents in health care facilities is of special concern, especially to airborne and droplet-borne respiratory diseases. to protect the health of public and health care workers the investigators will conduct a study to monitor indoor air quality and essential infectious aerosols in hospital(s). a questionnaire survey will be used to evaluate the relationships between employees' health and measured indoor environmental factors. the investigators will also examine whether the current indoor air quality recommendation of their country can reasonably reduce the risk of hospital infection. in addition, simple infectious aerosol indices will be established for future environmental management and monitoring in health care facilities.


Eligibility criteria:
inclusion criteria: * people who work in health care facilities exclusion criteria: * none

Keywords: indoor air quality infectious aerosols
evaluation of skin cleansers and skin protectants in management of incontinence-associated dermatitis

Conditions: Incontinence-associated Dermatitis

Summary: the aim of this study is to evaluate the efficacy of two different skin care regimens (3m cavilon advanced skin protectant with 3m no-rinse cleanser and coloplast conveen critic barrier with easi-cleanser) against standard care (skin wipes and conveen critic barrier) in the management of incontinence-associated dermatitis (iad) in hospitalised patients

the aim of this study is to evaluate the efficacy of two different skin care regimens (3m cavilon advanced skin protectant with 3m no-rinse cleanser and coloplast conveen critic barrier with easi-cleanser) against standard care (skin wipes and conveen critic barrier) in the management of incontinence-associated dermatitis (iad) in hospitalised patients. to date, there is no conclusive evidence on the "best treatment" for patients presenting with iad. this has led to current clinical practices tend to select iad products based on its cost and availability, which can be heavily influenced by marketing and commercialisation efforts. this study allows investigation of the effectiveness of iad products to ensure the provision of optimal care.

Eligibility criteria:
inclusion criteria: * aged 21 years and above at point of recruitment * diagnosed with iad * at regular risk of exposure to urine and faeces over their hospitalization exclusion criteria: * having a known allergy to the treatment products * haemodynamically unstable at point of assessment for study * unable to tolerate lateral positioning for skin cleansing and treatment application * pregnancy * having an existing skin disease at point of study that might lead to inaccurate iad assessment, such as herpes or scabies.
nitrocamptothecin in treating patients with glioblastoma multiforme

Conditions: Brain and Central Nervous System Tumors

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of nitrocamptothecin in treating patients who have glioblastoma multiforme.

objectives: i. assess the therapeutic activity and toxicities of nitrocamptothecin in patients with glioblastoma multiforme. ii. determine the overall response, duration of response, and progression free survival of these patients after this treatment. outline: this is a multicenter study. patients receive nitrocamptothecin orally daily on days 1-5. treatment continues every 7 days in the absence of disease progression or unacceptable toxicity. patients are followed every 6 weeks until disease progression in the absence of further treatment. projected accrual: a total of 14-25 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: histologically or cytologically confirmed glioblastoma multiforme recurrent disease confirmed by ct or mri bidimensionally measurable disease at least one lesion with the largest diameter at least 2 cm patient characteristics: age: 18 and over performance status: ecog 0-2 life expectancy: at least 3 months hematopoietic: absolute neutrophil count at least 2,000/mm3 platelet count at least 100,000/mm3 hepatic: bilirubin less than 1.5 times upper limit of normal (uln) alkaline phosphatase and transaminases no greater than 2.5 times uln (no greater than 5 times uln in case of liver metastases) renal: creatinine no greater than 1.7 mg/dl cardiovascular: no history of ischemic heart disease in past 6 months other: not pregnant or nursing fertile patients must use effective contraception no other prior or concurrent malignancies except cone biopsied carcinoma of the cervix or adequately treated basal or squamous cell skin carcinoma no other unstable systemic disease no active uncontrolled infection no psychological, familial, sociological, or geographical condition that would preclude study prior concurrent therapy: biologic therapy: not specified chemotherapy: at least 6 weeks since prior adjuvant chemotherapy no other prior or concurrent chemotherapy allowed endocrine therapy: concurrent corticosteroids allowed stable or decreasing dose for at least 2 weeks radiotherapy: no high dose radiotherapy, stereotactic radiosurgery, or internal radiotherapy unless recurrence is histologically confirmed at least 3 months since prior radiotherapy to the brain surgery: no prior surgery for recurrent brain tumor except biopsy at least 3 months since prior surgery for primary brain tumor other: no other concurrent anticancer therapy no other concurrent investigational therapy

Keywords: adult glioblastoma adult giant cell glioblastoma adult gliosarcoma
fibrostenotic eosinophilic esophagitis: assessment tools

Conditions: Eosinophilic Esophagitis

Summary: this protocol addresses a central hypothesis that fibrostenotic eosinophilic esophagitis (eoe) is characterized by abnormal esophageal structure and compliance compared to non fibrostenotic eoe and that distinctive cellular and molecular profiles predict the fibrostenotic phenotype. this study aims to define and assess the changes that occur in the structure and dynamics of the esophageal wall in pediatric eosinophilic esophagitis along with characterizing the histologic and molecular patterns in fibrostenotic eoe.


Eligibility criteria:
inclusion criteria: * scheduled to undergo a clinical upper endoscopy with biopsy exclusion criteria: * known connective tissue disorder * increased risk of bleeding * inflammatory bowel disease, celiac disease, eosinophilic gastroenteritis, or any autoimmune disease * other esophageal disease including known achalasia; history of caustic ingestion, esophageal surgery esophageal stricture for other known reason or other esophageal injury. * use of oral or intravenous steroids in the preceding 60 days. (swallowed topical fluticasone, budesonide, etc not included as exclusion criteria.)

Keywords: eosinophilic esophagitis esophageal stricture
nursing education intervention for maternal breastfeeding

Conditions: Breast Feeding; Postpartum Breast Disorders

Summary: an antenatal education intervention in primiparous women improves breastfeeding duration and reduces post-natal complications.

a randomized controlled clinical trial of an educational intervention was undertaken at a public hospital. the investigators compared a health education based on techniques to prevent complications and increase information about the benefits of breastfeeding with the usual practice. a group of nurses delivered the educational intervention. the trial involved randomization of 314 primiparous women. the analysis was by 'intention-to-treat'.

Eligibility criteria:
inclusion criteria: * primiparous women, * no contraindications to breastfeeding, * no skin disorders, * no breast surgery, * voluntary provision of data to enable their later localization. exclusion criteria: * women who planned to deliver their babies in other hospitals, * twin pregnancy

Keywords: breastfeeding nursing patient education as topic health knowledge, attitudes, practice hispanic americans.
pcv10 reactogenicity and immunogenicity study - malindi

Conditions: Pneumococcal Pneumonia

Summary: the world health organization has recommended that developing countries should incorporate pneumococcal conjugate vaccine (pcv) into their routine immunization schedules. the kenya ministry of health anticipates introducing a new formulation of pcv, pcv10, into the routine childhood immunization schedule in 2010. in the areas of kenya that have been designated to monitor the impact of vaccine, a catch-up campaign will be implemented to vaccinate children aged 12-59 months. pcv10 has been found to be safe and effective in infants. it is licensed for use in children up to 2 years of age, but its use as a primary series in children over age 12 months has not been evaluated. this study will assess the immunogenicity and reactogenicity of pcv10 first administered at an age of 12-59 months.


Eligibility criteria:
inclusion criteria: * age 12-59 months * written informed consent exclusion criteria: * current febrile illness (temperature \>38.5°c) * previous receipt of any pneumococcal vaccine * previous receipt of a dtp-containing vaccine after the 1st year of life * previous receipt of hepatitis a vaccine * severe malnutrition (mid upper arm circumference \<11.5 cm) or other serious medical condition (e.g., malignancy, aids, tuberculosis) * seizures within the previous 6 months or progressive neurological illness * known allergies to vaccines or vaccine components * resident in the kilifi demographic surveillance area * intention to leave the study area in the next 6 months

Keywords: pneumococcal pneumonia vaccine
community development teams to scale-up multidimensional treatment foster care (mtfc) in california

Conditions: Behavior Problems

Summary: the effects of using community development teams to increase the number of counties that successfully implement and sustain multidimensional treatment foster care programs is studied in a randomized trial in 40 california counties. mtfc is an alternative to group or residential placement for youth with severe conduct and emotional problems referred from the juvenile justice and child welfare systems.


Eligibility criteria:
inclusion criteria: * non-early adopters of evidence-based practice (mtfc) exclusion criteria: * placed fewer than 6 youth per year in group care

Keywords: individualized implementation community development teams
bronchiectasis: evaluation of an educational intervention

Conditions: Bronchiectasis

Summary: a study of an educational intervention of primary care practice physicians to assist in the identification of patients who have bronchiectasis and to assess the effectiveness of the specific didactic educational intervention targeting primary care physicians in the recognition of bronchiectasis.

a pilot study will be conducted for the purpose of evaluating an educational intervention (description in appendix a). as part of the educational intervention, primary care physician(s) will be trained in the use of an algorithm to guide assessment of patients seen with a respiratory chief complaint, and who have not previously been identified as having a diagnosis of be. we propose an evaluation of three primary care practice(s) to compare the number of patients identified in three three-month periods as having a diagnosis of be. the evaluation periods will be as follows: period 1) the three-month period immediately following the intervention, period 2) the three-month period immediately preceding the intervention, period 3) the three month period starting one year prior to the intervention.

Eligibility criteria:
inclusion criteria: 1. respiratory is the chief complaint 2. patient \> 35 years of age 3. seen in practice for \> 12 months exclusion criteria: 1) prior diagnosis with bronchiectasis

Keywords: bronchiectasis pulmonary exacerbations pulmonary infections
autologous stem cell transplantation for myeloma patients over 65 years

Conditions: Newly Diagnosed Myeloma Patient Above 65 Years Old

Summary: autologous stem cell transplantation remains the gold standard of treatment for newly diagnosed patients under the age of 65. even though it is also regularly performed above the age of 65, there are very few data in this patient population. the investigators will capture safety and efficacy data in that setting.

newly diagnosed myeloma patients above the age of 65 years will be treated the following way: bortezomib (velcade®) based induction treatment (either velcade dexamethasone, velcade thalidomide dexamethasone (vtd) or velcade cyclophosphamide dexamethasone (vcd)). after the induction phase, for patients at least in partial remission, a collection of peripheral blood stem cells (pbsc) is done according to each center practice. high dose melphalan (140 mg/m2) followed by pbsc autologous transplantation is then performed. three months post transplant, 2-3 cycles (similar to the initial induction phase) of consolidation are allowed.

Eligibility criteria:
inclusion criteria: * newly diagnosed mm, * age over 65, * measurable disease exclusion criteria: * patients less than 65 and/or not proceeding to autologous pbsc transplantation

Keywords: multiple myeloma autologous stem cell transplantation elderly patients